^
Association details:
| Biomarker: | AFP elevation |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) + galunisertib (LY2157299) (Phosphotransferase inhibitor, TGF-β1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Excerpt:
...Change From Baseline in Relationship of Biomarker Alpha-fetoprotein (AFP) to Overall Survival (OS)...Biomarker response was defined as a > 20% decrease in the biomarker AFP from baseline during 8 weeks of treatment. Data presented is median overall survival of those participants who achieved the defined biomarker response. Participants enrolled in Part A had a baseline AFP level of >1.5 upper limit normal (ULN). Participants enrolled in Part B had baseline AFP level <1.5 ULN...
Trial ID:
Source:
Title:
A Phase 2 Study of Galunisertib (TGF-ß1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Published date:
07/01/2019
Excerpt:
Patients with baseline AFP ≥ 400 ng/mL or patients with baseline TGF-β1 ≥ baseline median (1956 pg/mL) demonstrated trends toward longer TTP.
DOI:
10.14309/ctg.0000000000000056
Trial ID:
